MedTrace Logo

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

NCT02804100 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-11-01

No results posted yet for this study

Summary

A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Bronchial Neoplasms
  • Carcinoma, Bronchogenic
  • Lung Diseases
  • Lung Neoplasms

Sponsors & Collaborators

  • Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Wenfeng Li, Ph.D · First Affiliated Hospital of Wenzhou Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02804100 on ClinicalTrials.gov